Clinical trials: Motor Neuron Disease
Amyotrophic Lateral Sclerosis (ALS)
A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS
Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease that results in rapid decline in normal muscle function and tone leading to difficulties with mobility, eating, drinking, breathing, sleeping, and communicating.
- Trial name
- NCT02463825
- Testing
- Pimozide 2 mg per day, Pimozide 4 mg per day
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- University of Calgary
Parkinson's Disease (PD), Alzheimer's Disease (AD)
Quantification of Hsp90 in the Human Brain
This study tests the radiolabeled molecule ("tracer"), [¹¹C]HSP990, using positron emission tomography (PET) imaging to assess whether it can be used to measure levels of Heat Shock Protein 90 (Hsp90).
- Conditions
- Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- NCT07380204
- Testing
- [11C]HSP990 PET dosimetry, [11C]HSP990 PET test-retest, [11C]HSP990 simplified scan protocol
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Stroke, Amyotrophic Lateral Sclerosis
Auto-calibrating System for Upper Limb Disability Assessment, Neurological and Occupational Rehabilitation
This interventional, multicenter, low-intervention clinical trial aims to evaluate the usability, feasibility, safety, and preliminary clinical impact of a robotic rehabilitation system designed for upper limb rehabilitation in…
- Conditions
- Stroke, Amyotrophic Lateral Sclerosis, PARKINSON DISEASE (Disorder), Mild Cognitive Impairment (MCI)
- Trial name
- ASULDAR (NCT07636538)
- Testing
- Auto-calibrating System for Upper Limb disability Assessment, neurological and occupational Rehabilitation, conventional therapy
- Volunteers
- 30 people
- Sponsor
- University of Pavia
Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
This is a long-term follow-up safety and efficacy study of participants in clinical trials for spinal muscular atrophy (SMA) who were treated with onasemnogene abeparvovec-xioi.
- Conditions
- Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA
- Trial name
- NCT04042025
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 31 sites in United States, Australia and 7 more
- Volunteers
- 85 people
- Sponsor
- Novartis Gene Therapies
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
- Trial name
- ONYX (NCT05626855)
- Testing
- Apitegromab
- Where
- 49 sites in United States, Belgium and 7 more
- Volunteers
- 238 people
- Sponsor
- Scholar Rock, Inc.
Healthy Volunteers, Amyotrophic Lateral Sclerosis
Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET
The overall goal of this protocol is to evaluate microglial activation in the brain using [18F]PBR06 in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT03876002
- Testing
- [18F]PBR06
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid
Cerebrospinal Fluid Repository
The purpose of a CSF repository is to collect samples of spinal fluid from controls and patients with neurologic disorders including but not exclusively ALS, Dementia, CRPS, neuropathies, and other neuromuscular diseases.
- Conditions
- Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- CSF (NCT00714636)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Drexel University College of Medicine
Amyotrophic Lateral Sclerosis
Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)
The purpose of this trial is to study the effect of Memantine (uncompetitive, moderate affinity, NMDA receptor antagonist that binds to the NMDA receptor channel, and regulates the calcium influx into the neurons), a drug used to…
- Trial name
- NCT00353665
- Testing
- Memantine (Ebixa), riluzole
- Where
- Portugal
- Volunteers
- 63 people
- Sponsor
- University of Lisbon
Neurologic Disorder, Paralysis
SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis
The Synchron Motor Neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex.
- Conditions
- Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis
- Trial name
- NCT05041114
- Testing
- Motor Neuroprosthesis
- Where
- 3 sites in Australia
- Sponsor
- Synchron Medical, Inc.
Amyotrophic Lateral Sclerosis
Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS
This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical…
- Trial name
- de-ALS (NCT06598202)
- Testing
- exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Xuanwu Hospital, Beijing
Amyotrophic Lateral Sclerosis (ALS), Non Invasive Ventilation (NIV)
Dynamic Impact of NIV on Diaphragmatic Ultrasound in Patients With Amyotrophic Lateral Sclerosis
The goal of this pilot observational study is to learn about the dynamic impact of the non invasive ventilation on the diaphragm in patient with amyotrophic lateral sclerosis.
- Trial name
- EchoDia (NCT07170865)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Grenoble
Spinal Muscular Atrophy, SMA
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects <2 years old with 5q autosomal recessive SMA who have delayed motor milestones…
- Conditions
- Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
- Trial name
- OPAL (NCT07047144)
- Testing
- Apitegromab, Nusinersen, Risdiplam
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 52 people
- Sponsor
- Scholar Rock, Inc.
Spinal Muscular Atrophy Type II
Exoskeleton Impact on the Quality of Life on Patients With Spinal Muscular Atrophy
The purpose of this study is to evaluate the impact of the use of a pediatric exoskeleton on the quality of life of children, specifically in the psychological and care dimensions.
- Trial name
- NCT05416034
- Testing
- Use of the ATLAS 2025 exoskeleton at home
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- MarsiBionics
Amyotrophic Lateral Sclerosis
IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)
Patients with rapidly progressive ALS will be assigned to IC14 intravenously on Day 1-4. This 4-day course will be repeated on Days 8-11.
- Trial name
- NCT03474263
- Testing
- Biologic: IC14 (monoclonal antibody against human CD14)
- Where
- Australia
- Sponsor
- Implicit Bioscience
Prostate Cancer, Prostatic Neoplasms
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
This trial is designed to investigate the safety, dosing schedule, and efficacy of the combination treatment of Panobinostat (a histone deacetylase inhibitor) and hormone therapy for recurrent prostate cancer.
- Trial name
- NCT00878436
- Testing
- Panobinostat, Bicalutamide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- NYU Langone Health
Amyotrophic Lateral Sclerosis
Brain Excitability and Connectivity in Sensory-motor Pathways in ALS
The main objective is to determine the origin of somatosensory alteration in patients with ALS and to evaluate its impact on brain activity by coupling different imaging modalities and indirect electrophysiology.
- Trial name
- SOM_ALS (NCT03694132)
- Testing
- functional MRI, structural MRI, EEG/MEG
- Where
- France
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Amyotrophic Lateral Sclerosis
Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
1. Describe the distribution of ALS in mainland China, to explore the differences in the number of ALS in different times, regions and populations in order to further explore the causes affecting the distribution of ALS; 2.
- Trial name
- NCT04454892
- Testing
- Amyotrophic lateral sclerosis
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking University Third Hospital
Upper Motor Neuron Disease
Efficiency of Spatially Distributed Sequential Stimulation (Sdss) for Functional Electrical Stimulation (FES) of Upper Motor Neuron Syndrome (UMR) Patients
To determine whether Spatially Distributed Sequential Functional Electrical Stimulation is more effective than Standard Electrical Stimulation During Functional Electrical Stimulation in Upper Motor Neuron Patients
- Trial name
- SDSS_UMS (NCT06421753)
- Testing
- SDSS, Standard Electrical Stimulation During Functional Electrical Stimulation
- Where
- France
- Volunteers
- 10 people
- Sponsor
- UGECAM Rhône-Alpes
Amyotrophic Lateral Sclerosis
RAPA-501 Therapy of ALS Expanded Access Protocol
RAPA-501-ALS is an Intermediate-Size Expanded Access Trial of RAPA-501 autologous hybrid TREG/Th2 T stem cells in patients living with amyotrophic lateral sclerosis (pwALS).
- Trial name
- NCT06169176
- Testing
- RAPA-501 Autologous T stem cells
- Where
- 10 sites in United States
- Sponsor
- Rapa Therapeutics LLC
Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth
Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers
In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge.
- Conditions
- Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth, Muscular Dystrophy, Myotonic Dystrophy
- Trial name
- Myokinesis (NCT07321977)
- Testing
- Gait analysis via video capture
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Institut de Myologie, France